Skip to main content
Top
Published in: Diagnostic Pathology 1/2020

01-12-2020 | Merkel Cell Carcinoma | Case Report

A primary neuroendocrine tumor of the left ventricle presenting with diarrhea—an unusual experience and literature review

Authors: Chengfang Li, Jiajia Huang, Xiaorong Yang, Jinhua Xia, Gaoqiang Xu, Hong Zheng

Published in: Diagnostic Pathology | Issue 1/2020

Login to get access

Abstract

Background

Neuroendocrine tumors (NETs) can secrete bioactive amines in the bloodstream, resulting in the carcinoid syndrome characterized by diarrhea and flushing. The frequency of occurrence of primary cardiac neuroendocrine neoplasms is lesser than that of metastases, and hence, metastases must be adequately ruled out before diagnosis. Cardiac tumors, both primary and metastatic, mainly result in heart-related symptoms, such as heart failure and acquired valvular dysfunction. Here, we report a unique case of a primary left ventricular neuroendocrine tumor presenting with diarrhea.

Case presentation

A 51-year-old female complaining of intermittent diarrhea for 2 years was admitted to our hospital. Enhancement of total abdominal computed tomography scan, echocardiography, and magnetic resonance imaging indicated a mass in the left ventricle. The indexes of myocardial enzymes were normal. Histologically, round cells with well-differentiated neuroendocrine morphology were arranged in typical pseudo-glandular, trabecular, ribbon-like, and solid nest patterns. Immunohistochemically, the tumor cells were positive for cytokeratin, chromogranin, synaptophysin, and CD56. However, they were negative for caudal type homeobox 2, S100, paired box gene 8, thyroid transcription factor 1, and CD20, which ruled out the origin of gastrointestinal, pancreatic, lung, and Merkel cell carcinomas. The symptoms of diarrhea disappeared after the operation. The patient was asymptomatic at the 9-month follow-up.

Conclusion

Cardiac neuroendocrine tumors with diarrhea are considerably rare and related clinical research is limited. We presented a case and reviewed related articles to improve the identification, diagnosis, and management of patients with cardiac neuroendocrine tumors. The site of origin of a neuroendocrine tumor is clinically vital, and identification of an occult primary tumor using imaging modalities is necessary. Immunohistochemistry is well-suited to indicate the origin of the tumor. Regular follow-up is necessary for both poorly differentiated and well-differentiated cardiac neuroendocrine tumors. It is suggested to detect some neuroendocrinal markers for patients with unexplained reasons of diarrhea.
Literature
1.
go back to reference Bakaeen FG, Reardon MJ, Coselli JS, Miller CC, Howell JF, Lawrie GM, Espada R, Ramchandani MK, Noon GP, Weilbaecher DG, et al. Surgical outcome in 85 patients with primary cardiac tumors. Am J Surg. 2003;186(6):641–7.CrossRef Bakaeen FG, Reardon MJ, Coselli JS, Miller CC, Howell JF, Lawrie GM, Espada R, Ramchandani MK, Noon GP, Weilbaecher DG, et al. Surgical outcome in 85 patients with primary cardiac tumors. Am J Surg. 2003;186(6):641–7.CrossRef
2.
go back to reference Hofland J, Zandee WT, de Herder WW. Role of biomarker tests for diagnosis of neuroendocrine tumours. Nat Rev Endocrinol. 2018;14(11):656–69.CrossRef Hofland J, Zandee WT, de Herder WW. Role of biomarker tests for diagnosis of neuroendocrine tumours. Nat Rev Endocrinol. 2018;14(11):656–69.CrossRef
3.
go back to reference Lichtenauer M, Pichler T, Eder S, Mirna M, Magnes T, Wernly B, Paar V, Jung C, Prinz E, Seitelberger R, et al. Carcinoid heart disease involving the left heart: a case report and biomarker analysis. ESC Heart Fail. 2019;6(1):222–7.CrossRef Lichtenauer M, Pichler T, Eder S, Mirna M, Magnes T, Wernly B, Paar V, Jung C, Prinz E, Seitelberger R, et al. Carcinoid heart disease involving the left heart: a case report and biomarker analysis. ESC Heart Fail. 2019;6(1):222–7.CrossRef
4.
go back to reference Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S, Shih Y-CT, Yao JC. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18(4):525–34.CrossRef Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S, Shih Y-CT, Yao JC. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18(4):525–34.CrossRef
5.
go back to reference Perren A, Couvelard A, Scoazec J-Y, Costa F, Borbath I, Delle Fave G, Gorbounova V, Gross D, Grossma A, Jense RT, et al. ENETS consensus guidelines for the standards of Care in Neuroendocrine Tumors: pathology: diagnosis and prognostic stratification. Neuroendocrinology. 2017;105(3):196–200.CrossRef Perren A, Couvelard A, Scoazec J-Y, Costa F, Borbath I, Delle Fave G, Gorbounova V, Gross D, Grossma A, Jense RT, et al. ENETS consensus guidelines for the standards of Care in Neuroendocrine Tumors: pathology: diagnosis and prognostic stratification. Neuroendocrinology. 2017;105(3):196–200.CrossRef
6.
go back to reference Wißt T, Jehn C-F, Vierbuchen M, Starekova J. Solitary neuroendocrine carcinoma of the heart: a case report. Eur Heart J Case Rep. 2018;2(3):yty096.PubMedPubMedCentral Wißt T, Jehn C-F, Vierbuchen M, Starekova J. Solitary neuroendocrine carcinoma of the heart: a case report. Eur Heart J Case Rep. 2018;2(3):yty096.PubMedPubMedCentral
7.
go back to reference Carmona P, Lázaro J, Llagunes J, Cánovas S. Primary cardiac neuroendocrine carcinoma and minimally invasive cardiac surgery. Asian Cardiovasc Thorac Ann. 2012;20(6):721–3.CrossRef Carmona P, Lázaro J, Llagunes J, Cánovas S. Primary cardiac neuroendocrine carcinoma and minimally invasive cardiac surgery. Asian Cardiovasc Thorac Ann. 2012;20(6):721–3.CrossRef
8.
go back to reference Naqvi SY, Henry D, Furukawa S, Haber H. Primary neuroendocrine tumour of the right ventricle presenting with heart failure and cyanosis. BMJ Case Rep. 2016;2016:bcr2016–214810. Naqvi SY, Henry D, Furukawa S, Haber H. Primary neuroendocrine tumour of the right ventricle presenting with heart failure and cyanosis. BMJ Case Rep. 2016;2016:bcr2016–214810.
9.
go back to reference Guajardo-Salinas GE, Anaya-Ayala JE, Rice DC, Moran CA, Reardon MJ. Primary high-grade neuroendocrine carcinoma of the heart. Tex Heart Inst J. 2013;40(1):71–4.PubMedPubMedCentral Guajardo-Salinas GE, Anaya-Ayala JE, Rice DC, Moran CA, Reardon MJ. Primary high-grade neuroendocrine carcinoma of the heart. Tex Heart Inst J. 2013;40(1):71–4.PubMedPubMedCentral
10.
go back to reference Rogers MP, Thomas S, Nallamshetty L, Hooker R. Primary neuroendocrine tumour of the left ventricle. Eur J Cardio-Thoracic Surgery. 2020;57(4):806–8. Rogers MP, Thomas S, Nallamshetty L, Hooker R. Primary neuroendocrine tumour of the left ventricle. Eur J Cardio-Thoracic Surgery. 2020;57(4):806–8.
11.
go back to reference Öberg KE. Gastrointestinal neuroendocrine tumors. Ann Oncol. 2010;21(Suppl 7):vii72–80.CrossRef Öberg KE. Gastrointestinal neuroendocrine tumors. Ann Oncol. 2010;21(Suppl 7):vii72–80.CrossRef
12.
go back to reference Strosberg JR, Coppola D, Klimstra DS, Phan AT, Kulke MH, Wiseman GA, Kvols LK. North American neuroendocrine tumor S: the NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 2010;39(6):799–800.CrossRef Strosberg JR, Coppola D, Klimstra DS, Phan AT, Kulke MH, Wiseman GA, Kvols LK. North American neuroendocrine tumor S: the NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 2010;39(6):799–800.CrossRef
13.
go back to reference Lips CJM, Lentjes EGWM, Höppener JWM. The spectrum of carcinoid tumours and carcinoid syndromes. Ann Clin Biochem. 2003;40(Pt 6):612–27.CrossRef Lips CJM, Lentjes EGWM, Höppener JWM. The spectrum of carcinoid tumours and carcinoid syndromes. Ann Clin Biochem. 2003;40(Pt 6):612–27.CrossRef
14.
go back to reference Bertrand PP, Bertrand RL. Serotonin release and uptake in the gastrointestinal tract. Auton Neurosci. 2010;153(1–2):47–57.CrossRef Bertrand PP, Bertrand RL. Serotonin release and uptake in the gastrointestinal tract. Auton Neurosci. 2010;153(1–2):47–57.CrossRef
15.
go back to reference Mawe GM, Hoffman JM. Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol. 2013;10(8):473–86.CrossRef Mawe GM, Hoffman JM. Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol. 2013;10(8):473–86.CrossRef
16.
go back to reference Jann H, Wertenbruch T, Pape U, Ozcelik C, Denecke T, Mehl S, Wiedenmann B, Pavel M. A matter of the heart: myocardial metastases in neuroendocrine tumors. Horm Metab Res. 2010;42(13):967–76.CrossRef Jann H, Wertenbruch T, Pape U, Ozcelik C, Denecke T, Mehl S, Wiedenmann B, Pavel M. A matter of the heart: myocardial metastases in neuroendocrine tumors. Horm Metab Res. 2010;42(13):967–76.CrossRef
17.
go back to reference Pasieka JL, Schnell G, Abdel-Aty H, Rorstad O. Metastatic midgut carcinoid to the heart demonstrated on cardiac magnetic resonance imaging. Am J Clin Oncol. 2009;32(3):328–9.CrossRef Pasieka JL, Schnell G, Abdel-Aty H, Rorstad O. Metastatic midgut carcinoid to the heart demonstrated on cardiac magnetic resonance imaging. Am J Clin Oncol. 2009;32(3):328–9.CrossRef
18.
go back to reference Minicucci MF, Zornoff LAM, Okoshi MP, Bueno SP, Matsubara BB, Azevedo PS, Duarte DR, Paiva SAR, Marques M, Matsubara LS. Heart failure due to right ventricular metastatic neuroendocrine tumor. Int J Cardiol. 2008;126(2):e25–6.CrossRef Minicucci MF, Zornoff LAM, Okoshi MP, Bueno SP, Matsubara BB, Azevedo PS, Duarte DR, Paiva SAR, Marques M, Matsubara LS. Heart failure due to right ventricular metastatic neuroendocrine tumor. Int J Cardiol. 2008;126(2):e25–6.CrossRef
19.
go back to reference Drake WM, Jenkins PJ, Phillips RR, Lowe DG, Grossman AB, Besser GM, Wass JA. Intracardiac metastases from neuroendocrine tumours. Clin Endocrinol. 1997;46(4):517–22.CrossRef Drake WM, Jenkins PJ, Phillips RR, Lowe DG, Grossman AB, Besser GM, Wass JA. Intracardiac metastases from neuroendocrine tumours. Clin Endocrinol. 1997;46(4):517–22.CrossRef
20.
go back to reference Jaffee IM, Rahmani M, Singhal MG, Younes M. Expression of the intestinal transcription factor CDX2 in carcinoid tumors is a marker of midgut origin. Arch Pathol Lab Med. 2006;130(10):1522–6.PubMed Jaffee IM, Rahmani M, Singhal MG, Younes M. Expression of the intestinal transcription factor CDX2 in carcinoid tumors is a marker of midgut origin. Arch Pathol Lab Med. 2006;130(10):1522–6.PubMed
21.
go back to reference Lin X, Saad RS, Luckasevic TM, Silverman JF, Liu Y. Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin. Appl Immunohistochem Mol Morphol. 2007;15(4):407–14.CrossRef Lin X, Saad RS, Luckasevic TM, Silverman JF, Liu Y. Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin. Appl Immunohistochem Mol Morphol. 2007;15(4):407–14.CrossRef
22.
go back to reference Yang MX, Coates RF, Ambaye A, Cortright V, Mitchell JM, Buskey AM, Zubarik R, Liu JG, Ades S, Barry MM. NKX2.2, PDX-1 and CDX-2 as potential biomarkers to differentiate well-differentiated neuroendocrine tumors. Biomark Res. 2018;6:15.CrossRef Yang MX, Coates RF, Ambaye A, Cortright V, Mitchell JM, Buskey AM, Zubarik R, Liu JG, Ades S, Barry MM. NKX2.2, PDX-1 and CDX-2 as potential biomarkers to differentiate well-differentiated neuroendocrine tumors. Biomark Res. 2018;6:15.CrossRef
23.
go back to reference Kaufmann O, Dietel M. Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathology. 2000;36(5):415–20.CrossRef Kaufmann O, Dietel M. Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathology. 2000;36(5):415–20.CrossRef
24.
go back to reference Oliveira AM, Tazelaar HD, Myers JL, Erickson LA, Lloyd RV. Thyroid transcription factor-1 distinguishes metastatic pulmonary from well-differentiated neuroendocrine tumors of other sites. Am J Surg Pathol. 2001;25(6):815–9.CrossRef Oliveira AM, Tazelaar HD, Myers JL, Erickson LA, Lloyd RV. Thyroid transcription factor-1 distinguishes metastatic pulmonary from well-differentiated neuroendocrine tumors of other sites. Am J Surg Pathol. 2001;25(6):815–9.CrossRef
25.
go back to reference Agoff SN, Lamps LW, Philip AT, Amin MB, Schmidt RA, True LD, Folpe AL. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol. 2000;13(3):238–42.CrossRef Agoff SN, Lamps LW, Philip AT, Amin MB, Schmidt RA, True LD, Folpe AL. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol. 2000;13(3):238–42.CrossRef
26.
go back to reference Inafuku K, Yokose T, Ito H, Eriguchi D, Samejima J, Nagashima T, Nakayama H, Suzuki M, Yamada K, Masuda M. Two cases of lung neuroendocrine carcinoma with carcinoid morphology. Diagn Pathol. 2019;14(1):104.CrossRef Inafuku K, Yokose T, Ito H, Eriguchi D, Samejima J, Nagashima T, Nakayama H, Suzuki M, Yamada K, Masuda M. Two cases of lung neuroendocrine carcinoma with carcinoid morphology. Diagn Pathol. 2019;14(1):104.CrossRef
27.
go back to reference Long KB, Srivastava A, Hirsch MS, Hornick JL. PAX8 expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors. Am J Surg Pathol. 2010;34(5):723–9.CrossRef Long KB, Srivastava A, Hirsch MS, Hornick JL. PAX8 expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors. Am J Surg Pathol. 2010;34(5):723–9.CrossRef
28.
go back to reference Sangoi AR, Ohgami RS, Pai RK, Beck AH, McKenney JK, Pai RK. PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma. Mod Pathol. 2011;24(3):412–24.CrossRef Sangoi AR, Ohgami RS, Pai RK, Beck AH, McKenney JK, Pai RK. PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma. Mod Pathol. 2011;24(3):412–24.CrossRef
29.
go back to reference Haynes CM, Sangoi AR, Pai RK. PAX8 is expressed in pancreatic well-differentiated neuroendocrine tumors and in extrapancreatic poorly differentiated neuroendocrine carcinomas in fine-needle aspiration biopsy specimens. Cancer Cytopathol. 2011;119(3):193–201.CrossRef Haynes CM, Sangoi AR, Pai RK. PAX8 is expressed in pancreatic well-differentiated neuroendocrine tumors and in extrapancreatic poorly differentiated neuroendocrine carcinomas in fine-needle aspiration biopsy specimens. Cancer Cytopathol. 2011;119(3):193–201.CrossRef
30.
go back to reference Moll R, Löwe A, Laufer J, Franke WW. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol. 1992;140(2):427–47.PubMedPubMedCentral Moll R, Löwe A, Laufer J, Franke WW. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol. 1992;140(2):427–47.PubMedPubMedCentral
31.
go back to reference Tanaka Y, Sano T, Qian ZR, Hirokawa M. Expression of adhesion molecules and cytokeratin 20 in merkel cell carcinomas. Endocr Pathol. 2004;15(2):117–29.CrossRef Tanaka Y, Sano T, Qian ZR, Hirokawa M. Expression of adhesion molecules and cytokeratin 20 in merkel cell carcinomas. Endocr Pathol. 2004;15(2):117–29.CrossRef
32.
go back to reference Bellizzi AM. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistry. Adv Anat Pathol. 2013;20(5):285–314.CrossRef Bellizzi AM. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistry. Adv Anat Pathol. 2013;20(5):285–314.CrossRef
33.
go back to reference Koo J, Zhou X, Moschiano E, De Peralta-Venturina M, Mertens RB, Dhall D. The immunohistochemical expression of islet 1 and PAX8 by rectal neuroendocrine tumors should be taken into account in the differential diagnosis of metastatic neuroendocrine tumors of unknown primary origin. Endocr Pathol. 2013;24(4):184–90.CrossRef Koo J, Zhou X, Moschiano E, De Peralta-Venturina M, Mertens RB, Dhall D. The immunohistochemical expression of islet 1 and PAX8 by rectal neuroendocrine tumors should be taken into account in the differential diagnosis of metastatic neuroendocrine tumors of unknown primary origin. Endocr Pathol. 2013;24(4):184–90.CrossRef
Metadata
Title
A primary neuroendocrine tumor of the left ventricle presenting with diarrhea—an unusual experience and literature review
Authors
Chengfang Li
Jiajia Huang
Xiaorong Yang
Jinhua Xia
Gaoqiang Xu
Hong Zheng
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2020
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/s13000-020-00935-x

Other articles of this Issue 1/2020

Diagnostic Pathology 1/2020 Go to the issue